TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials ASCO Guidelines provide recommendations with comprehensive ...
Germline testing is a genetic screening that looks for inherited gene mutations found in every cell. It can identify ...
The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...
Clinical Implementation of Expanded Solid Tumor Fusion Detection With Whole-Transcriptome Sequencing at an Academic Cancer Center One hundred twenty-two participants completed the survey. The majority ...
MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S.
Please provide your email address to receive an email when new articles are posted on . Black men with prostate cancer had significantly greater odds of having alterations in immunotherapy targets ...
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results